Pembrolizumab plus lenvatinib for all advanced endometrial cancer? Maybe not
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
You do not have access to the full text of this article, the first page of the PDF of this article appears above.
Contributors EP is the sole contributor.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests EP works as an internal expert for GSK.
Provenance and peer review Not commissioned; internally peer reviewed.